{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:08:34Z","timestamp":1789391314913,"version":"build-2803163510"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Foundation","award":["MCB 2141650"],"award-info":[{"award-number":["MCB 2141650"]}]},{"name":"National Science Foundation","award":["MCB 2141650"],"award-info":[{"award-number":["MCB 2141650"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM108563"],"award-info":[{"award-number":["T32GM108563"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM108563"],"award-info":[{"award-number":["T32GM108563"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA265709"],"award-info":[{"award-number":["U01CA265709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA265709"],"award-info":[{"award-number":["U01CA265709"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug resistance is a constantly evolving challenge. The allosteric inhibitor asciminib is a novel therapy for chronic myelogenous leukemia (CML) that targets the myristoyl pocket of the BCR::ABL1 kinase. While it can overcome resistance to active-site inhibitors like imatinib, new resistance mutations to asciminib are emerging. The complete landscape of these mutations, particularly those outside the kinase domain or those arising from epistatic interactions between mutations, are not well understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study employed a dual functional genomics approach in CML cell line models. A high-throughput adenosine base editing (ABE) screen was used to identify broad hotspots of asciminib resistance across the entire BCR::ABL1 protein. Deep mutational scanning (DMS) was then used to create a high-resolution map of all possible amino acid changes within these hotspots. An \u201cedit-on-edit\u201d screen was performed to investigate epistasis by introducing a library of mutations into a cell line that was pre-edited to incorporate the common imatinib-resistance mutation, Y253H. Finally, a novel F\u00f6rster resonance energy transfer (FRET) biosensor was developed to measure the conformational state of BCR::ABL1 in live cells and link it to drug sensitivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The screens identified 279 asciminib resistance mutations and revealed resistance hotspots distributed across the SH3, SH2, and kinase domains, in contrast to imatinib resistance, which is largely confined to the kinase domain. The study uncovered a potent epistatic interaction between a mutation in the SH3 domain (V73A) and a mutation in the kinase domain P-loop (Y253H), which synergistically conferred high-level resistance. The FRET biosensor demonstrated that asciminib resistance mutations tend to destabilize the \u201cclosed\u201d inactive conformation of the ABL1 kinase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The landscape of asciminib resistance is broader and more complex than previously appreciated, involving mutations across multiple domains that disrupt ABL1 autoinhibition. Epistasis between mutations acquired during sequential therapies can create unexpected and potent resistance. However, these diverse genetic resistance mechanisms converge on a single biophysical measurement of the openness of the active ABL1 conformation. This provides a unified framework for understanding asciminib resistance and underscores the need for routine clinical resistance monitoring to include the SH3 and SH2 domains in first line and later line therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-026-01679-x","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:05:46Z","timestamp":1782558346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual functional genomics reveals a broad and convergent landscape of asciminib resistance in BCR::ABL1"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1846-5469","authenticated-orcid":false,"given":"Ivan","family":"Sokirniy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5034-6303","authenticated-orcid":false,"given":"Zeyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"1679_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.molcel.2006.01.035","volume":"21","author":"B Nagar","year":"2006","unstructured":"Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, et al. Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell. 2006;21:787\u201398. https:\/\/doi.org\/10.1016\/j.molcel.2006.01.035.","journal-title":"Mol Cell"},{"key":"1679_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0092-8674(03)00194-6","volume":"112","author":"B Nagar","year":"2003","unstructured":"Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase. Cell. 2003;112:859\u201371. https:\/\/doi.org\/10.1016\/S0092-8674(03)00194-6.","journal-title":"Cell"},{"key":"1679_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr\u2013Abl tyrosine kinases. Nat Rev Mol Cell Biol Nat Publishing Group. 2004;5:33\u201344. https:\/\/doi.org\/10.1038\/nrm1280.","journal-title":"Nat Rev Mol Cell Biol Nat Publishing Group"},{"key":"1679_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1097-2765(03)00274-0","volume":"12","author":"KM Smith","year":"2003","unstructured":"Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through Its SH3 Domain. Mol Cell. 2003;12:27\u201337. https:\/\/doi.org\/10.1016\/S1097-2765(03)00274-0.","journal-title":"Mol Cell"},{"key":"1679_CR5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr\u2013Abl positive cells. Nat Med Nat Publishing Group. 1996;2:561\u20136. https:\/\/doi.org\/10.1038\/nm0596-561.","journal-title":"Nat Med Nat Publishing Group"},{"key":"1679_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0960-894X(96)00601-4","volume":"7","author":"J Zimmermann","year":"1997","unstructured":"Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB. Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives. Bioorg Med Chem Lett. 1997;7:187\u201392. https:\/\/doi.org\/10.1016\/S0960-894X(96)00601-4.","journal-title":"Bioorg Med Chem Lett"},{"key":"1679_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","volume":"249","author":"JV Melo","year":"2007","unstructured":"Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 2007;249:121\u201332. https:\/\/doi.org\/10.1016\/j.canlet.2006.07.010.","journal-title":"Cancer Lett"},{"key":"1679_CR8","doi-asserted-by":"publisher","unstructured":"Hoemberger M, Pitsawong W, Kern D. Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase. Proc Natl Acad Sci. Proceedings of the National Academy of Sciences; 2020;117:19221\u20137. https:\/\/doi.org\/10.1073\/pnas.1919221117.","DOI":"10.1073\/pnas.1919221117"},{"key":"1679_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/nmeth.4027","volume":"13","author":"Y Ma","year":"2016","unstructured":"Ma Y, Zhang J, Yin W, Zhang Z, Song Y, Chang X. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat Methods. 2016;13:1029\u201335. https:\/\/doi.org\/10.1038\/nmeth.4027.","journal-title":"Nat Methods"},{"key":"1679_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ. Mechanisms of Autoinhibition and STI-571\/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL. Cell Elsevier. 2003;112:831\u201343. https:\/\/doi.org\/10.1016\/S0092-8674(03)00190-9.","journal-title":"Cell Elsevier"},{"key":"1679_CR11","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"J Schoepfer","year":"2018","unstructured":"Schoepfer J, Jahnke W, Berellini G, Buonamici S, Cotesta S, Cowan-Jacob SW, et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem Am Chem Soc. 2018;61:8120\u201335. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01040.","journal-title":"J Med Chem Am Chem Soc"},{"key":"1679_CR12","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1038\/s41375-024-02278-8","volume":"38","author":"JE Cortes","year":"2024","unstructured":"Cortes JE, Sasaki K, Kim D-W, Hughes TP, Etienne G, Mauro MJ, et al. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after \u2265\u20091 prior tyrosine kinase inhibitor: 2-year follow-up results. Leuk Nat Publishing Group. 2024;38:1522\u201333. https:\/\/doi.org\/10.1038\/s41375-024-02278-8.","journal-title":"Leuk Nat Publishing Group"},{"key":"1679_CR13","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"TP Hughes","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. N Engl J Med Mass Med Soc. 2019;381:2315\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1902328.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"1679_CR14","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41375-024-02411-7","volume":"38","author":"AJ Innes","year":"2024","unstructured":"Innes AJ, Hayden C, Orovboni V, Claudiani S, Fernando F, Khan A, et al. Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy. Leuk Nat Publishing Group. 2024;38:2443\u201355. https:\/\/doi.org\/10.1038\/s41375-024-02411-7.","journal-title":"Leuk Nat Publishing Group"},{"key":"1679_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jmgm.2019.03.018","volume":"89","author":"J-Y Zhan","year":"2019","unstructured":"Zhan J-Y, Ma J, Zheng Q-C. Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL. J Mol Graph Model. 2019;89:242\u20139. https:\/\/doi.org\/10.1016\/j.jmgm.2019.03.018.","journal-title":"J Mol Graph Model"},{"key":"1679_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/blood.2023022538","volume":"144","author":"A Leyte-Vidal","year":"2024","unstructured":"Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, et al. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 2024;144:639\u201345. https:\/\/doi.org\/10.1182\/blood.2023022538.","journal-title":"Blood"},{"key":"1679_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.14740\/wjon1818","volume":"15","author":"S Okabe","year":"2024","unstructured":"Okabe S, Moriyama M, Gotoh A. Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells. World J Oncol. 2024;15:319\u201324. https:\/\/doi.org\/10.14740\/wjon1818.","journal-title":"World J Oncol"},{"key":"1679_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nature21702","volume":"543","author":"AA Wylie","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1. Nature. Nat Publishing Group. 2017;543:733\u20137. https:\/\/doi.org\/10.1038\/nature21702.","journal-title":"Nat Publishing Group"},{"key":"1679_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"CA Eide","year":"2019","unstructured":"Eide CA, Zabriskie MS, Stevens SLS, Antelope O, Vellore NA, Than H, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell Elsevier. 2019;36:431\u2013e4435. https:\/\/doi.org\/10.1016\/j.ccell.2019.08.004.","journal-title":"Cancer Cell Elsevier"},{"key":"1679_CR20","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41375-024-02314-7","volume":"38","author":"IB Leske","year":"2024","unstructured":"Leske IB, Hantschel O. The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib. Leuk Nat Publishing Group. 2024;38:2041\u20135. https:\/\/doi.org\/10.1038\/s41375-024-02314-7.","journal-title":"Leuk Nat Publishing Group"},{"key":"1679_CR21","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1038\/s41375-024-02353-0","volume":"38","author":"A Leyte-Vidal","year":"2024","unstructured":"Leyte-Vidal A, DeFilippis R, Outhwaite IR, Kwan I, Lee JY, Leavitt C, et al. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leuk Nat Publishing Group. 2024;38:2046\u201350. https:\/\/doi.org\/10.1038\/s41375-024-02353-0.","journal-title":"Leuk Nat Publishing Group"},{"key":"1679_CR22","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.trecan.2016.05.010","volume":"2","author":"JJ Lin","year":"2016","unstructured":"Lin JJ, Shaw AT. Resisting Resistance: Targeted Therapies in Lung Cancer. Trends Cancer. 2016;2:350\u201364. https:\/\/doi.org\/10.1016\/j.trecan.2016.05.010.","journal-title":"Trends Cancer"},{"key":"1679_CR23","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018;29:i10\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx703.","journal-title":"Ann Oncol"},{"key":"1679_CR24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"S Soverini","year":"2014","unstructured":"Soverini S, De Benedittis C, Papayannidis C, Paolini S, Venturi C, Iacobucci I, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome\u2013positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120:1002\u20139. https:\/\/doi.org\/10.1002\/cncr.28522.","journal-title":"Cancer"},{"key":"1679_CR25","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","volume":"391","author":"GV Long","year":"2024","unstructured":"Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med Mass Med Soc. 2024;391:1709\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2404139.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"1679_CR26","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet Elsevier. 2015;386:444\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(15)60898-4.","journal-title":"Lancet Elsevier"},{"key":"1679_CR27","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020;37:530\u201342. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006.","journal-title":"Cancer Cell"},{"key":"1679_CR28","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1182\/blood-2009-08-215939","volume":"114","author":"S Branford","year":"2009","unstructured":"Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 2009;114:5426\u201335. https:\/\/doi.org\/10.1182\/blood-2009-08-215939.","journal-title":"Blood"},{"key":"1679_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41929-024-01117-4","volume":"7","author":"C Fr\u00f6hlich","year":"2024","unstructured":"Fr\u00f6hlich C, Bunzel HA, Buda K, Mulholland AJ, van der Kamp MW, Johnsen PJ, et al. Epistasis arises from shifting the rate-limiting step during enzyme evolution of a \u03b2-lactamase. Nat Catal Nat Publishing Group. 2024;7:499\u2013509. https:\/\/doi.org\/10.1038\/s41929-024-01117-4.","journal-title":"Nat Catal Nat Publishing Group"},{"key":"1679_CR30","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1016\/j.jmb.2019.03.020","volume":"431","author":"CE Gonzalez","year":"2019","unstructured":"Gonzalez CE, Ostermeier M. Pervasive pairwise intragenic epistasis among sequential mutations in TEM-1 \u03b2-lactamase. J Mol Biol. 2019;431:1981\u201392. https:\/\/doi.org\/10.1016\/j.jmb.2019.03.020.","journal-title":"J Mol Biol"},{"key":"1679_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","volume":"26","author":"MS Zabriskie","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. Cancer Cell. 2014;26:428\u201342. https:\/\/doi.org\/10.1016\/j.ccr.2014.07.006.","journal-title":"Cancer Cell"},{"key":"1679_CR32","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.3324\/haematol.2017.176347","volume":"103","author":"K Byrgazov","year":"2018","unstructured":"Byrgazov K, Lucini CB, Valent P, Hantschel O, Lion T. BCR-ABL1 compound mutants display differential and dose-dependent responses to ponatinib. Haematologica. 2018;103:e10\u20132. https:\/\/doi.org\/10.3324\/haematol.2017.176347.","journal-title":"Haematologica"},{"key":"1679_CR33","doi-asserted-by":"publisher","first-page":"gkaf738","DOI":"10.1093\/nar\/gkaf738","volume":"53","author":"I Sokirniy","year":"2025","unstructured":"Sokirniy I, Inam H, Tomaszkiewicz M, Reynolds J, McCandlish D, Pritchard J. A side-by-side comparison of variant function measurements using deep mutational scanning and base editing. Nucleic Acids Res. 2025;53:gkaf738. https:\/\/doi.org\/10.1093\/nar\/gkaf738.","journal-title":"Nucleic Acids Res"},{"key":"1679_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/ejh.14330","volume":"114","author":"A Shacham-Abulafia","year":"2025","unstructured":"Shacham-Abulafia A, Volcheck Y, Ellis M, Shapira S, Tavor S, Gourevitch A, et al. Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia. Eur J Haematol. 2025;114:258\u201363. https:\/\/doi.org\/10.1111\/ejh.14330.","journal-title":"Eur J Haematol"},{"key":"1679_CR35","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1038\/s41598-019-41277-z","volume":"9","author":"BW Stringer","year":"2019","unstructured":"Stringer BW, Day BW, D\u2019Souza RCJ, Jamieson PR, Ensbey KS, Bruce ZC, et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. Sci Rep Nat Publishing Group. 2019;9:4902. https:\/\/doi.org\/10.1038\/s41598-019-41277-z.","journal-title":"Sci Rep Nat Publishing Group"},{"key":"1679_CR36","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3389\/fbioe.2016.00099","volume":"4","author":"L Chicaybam","year":"2017","unstructured":"Chicaybam L, Barcelos C, Peixoto B, Carneiro M, Limia CG, Redondo P, et al. An Efficient Electroporation Protocol for the Genetic Modification of Mammalian Cells. Front Bioeng Biotechnol. 2017;4:99. https:\/\/doi.org\/10.3389\/fbioe.2016.00099.","journal-title":"Front Bioeng Biotechnol"},{"key":"1679_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2105-13-134","volume":"13","author":"J Ye","year":"2012","unstructured":"Ye J, Coulouris G, Zaretskaya I, Cutcutache I, Rozen S, Madden TL. Primer-BLAST: A tool to design target-specific primers for polymerase chain reaction. BMC Bioinformatics. 2012;13:134. https:\/\/doi.org\/10.1186\/1471-2105-13-134.","journal-title":"BMC Bioinformatics"},{"key":"1679_CR38","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41467-022-28884-7","volume":"13","author":"AK Sangree","year":"2022","unstructured":"Sangree AK, Griffith AL, Szegletes ZM, Roy P, DeWeirdt PC, Hegde M, et al. Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2. Nat Commun Nat Publishing Group. 2022;13:1318. https:\/\/doi.org\/10.1038\/s41467-022-28884-7.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"1679_CR39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1093\/nar\/24.4.596","volume":"24","author":"M Jordan","year":"1996","unstructured":"Jordan M, Schallhorn A, Wurm FM. Transfecting Mammalian Cells: Optimization of Critical Parameters Affecting Calcium-Phosphate Precipitate Formation. Nucleic Acids Res. 1996;24:596\u2013601. https:\/\/doi.org\/10.1093\/nar\/24.4.596.","journal-title":"Nucleic Acids Res"},{"key":"1679_CR40","doi-asserted-by":"publisher","first-page":"W272","DOI":"10.1093\/nar\/gkw398","volume":"44","author":"K Labun","year":"2016","unstructured":"Labun K, Montague TG, Gagnon JA, Thyme SB, Valen E. CHOPCHOP v2: a web tool for the next generation of CRISPR genome engineering. Nucleic Acids Res. 2016;44:W272\u20136. https:\/\/doi.org\/10.1093\/nar\/gkw398.","journal-title":"Nucleic Acids Res"},{"key":"1679_CR41","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1093\/nar\/gkx181","volume":"45","author":"A Read","year":"2017","unstructured":"Read A, Gao S, Batchelor E, Luo J. Flexible CRISPR library construction using parallel oligonucleotide retrieval. Nucleic Acids Res. 2017;45:e101. https:\/\/doi.org\/10.1093\/nar\/gkx181.","journal-title":"Nucleic Acids Res"},{"key":"1679_CR42","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.molcel.2017.08.008","volume":"67","author":"P Billon","year":"2017","unstructured":"Billon P, Bryant EE, Joseph SA, Nambiar TS, Hayward SB, Rothstein R, et al. CRISPR-Mediated Base Editing Enables Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons. Mol Cell Elsevier. 2017;67:1068\u2013e10794. https:\/\/doi.org\/10.1016\/j.molcel.2017.08.008.","journal-title":"Mol Cell Elsevier"},{"key":"1679_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/B978-0-12-418687-3.00013-6","volume":"529","author":"CM Koh","year":"2013","unstructured":"Koh CM. Isolation of genomic DNA from mammalian cells. Methods Enzymol. 2013;529:161\u20139. https:\/\/doi.org\/10.1016\/B978-0-12-418687-3.00013-6.","journal-title":"Methods Enzymol"},{"key":"1679_CR44","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1038\/s41467-018-07901-8","volume":"9","author":"KR Sanson","year":"2018","unstructured":"Sanson KR, Hanna RE, Hegde M, Donovan KF, Strand C, Sullender ME, et al. Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities. Nat Commun Nat Publishing Group. 2018;9:5416. https:\/\/doi.org\/10.1038\/s41467-018-07901-8.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"1679_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17:10\u20132. https:\/\/doi.org\/10.14806\/ej.17.1.200.","journal-title":"EMBnet J"},{"key":"1679_CR46","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2009-10-3-r25","volume":"10","author":"B Langmead","year":"2009","unstructured":"Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25. https:\/\/doi.org\/10.1186\/gb-2009-10-3-r25.","journal-title":"Genome Biol"},{"key":"1679_CR47","doi-asserted-by":"publisher","first-page":"btad547","DOI":"10.1093\/bioinformatics\/btad547","volume":"39","author":"B Muzellec","year":"2023","unstructured":"Muzellec B, Tele\u0144czuk M, Cabeli V, Andreux M. PyDESeq2: a python package for bulk RNA-seq differential expression analysis. Bioinforma Oxf Engl. 2023;39:btad547. https:\/\/doi.org\/10.1093\/bioinformatics\/btad547.","journal-title":"Bioinforma Oxf Engl"},{"key":"1679_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17:122. https:\/\/doi.org\/10.1186\/s13059-016-0974-4.","journal-title":"Genome Biol"},{"key":"1679_CR49","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cell.2020.05.037","volume":"182","author":"M Arbab","year":"2020","unstructured":"Arbab M, Shen MW, Mok B, Wilson C, Matuszek \u017b, Cassa CA, et al. Determinants of Base Editing Outcomes from Target Library Analysis and Machine Learning. Cell. 2020;182:463\u2013e48030. https:\/\/doi.org\/10.1016\/j.cell.2020.05.037.","journal-title":"Cell"},{"key":"1679_CR50","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s12033-012-9528-5","volume":"53","author":"W Denning","year":"2013","unstructured":"Denning W, Das S, Guo S, Xu J, Kappes JC, Hel Z. Optimization of the transductional efficiency of lentiviral vectors: effect of sera and polycations. Mol Biotechnol. 2013;53:308\u201314. https:\/\/doi.org\/10.1007\/s12033-012-9528-5.","journal-title":"Mol Biotechnol"},{"key":"1679_CR51","doi-asserted-by":"publisher","first-page":"101227","DOI":"10.1016\/j.xcrm.2023.101227","volume":"4","author":"C Liu","year":"2023","unstructured":"Liu C, Leighow SM, McIlroy K, Lu M, Dennis KA, Abello K, et al. Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing. Cell Rep Med. 2023;4:101227. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101227.","journal-title":"Cell Rep Med"},{"key":"1679_CR52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.1923","volume":"9","author":"B Langmead","year":"2012","unstructured":"Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. Nat Publishing Group. 2012;9:357\u20139. https:\/\/doi.org\/10.1038\/nmeth.1923.","journal-title":"Nat Publishing Group"},{"key":"1679_CR53","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","volume":"17","author":"P Virtanen","year":"2020","unstructured":"Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods Nat Publishing Group. 2020;17:261\u201372. https:\/\/doi.org\/10.1038\/s41592-019-0686-2.","journal-title":"Nat Methods Nat Publishing Group"},{"key":"1679_CR54","doi-asserted-by":"publisher","first-page":"5464","DOI":"10.1038\/s41467-025-60641-4","volume":"16","author":"Z Jiang","year":"2025","unstructured":"Jiang Z, van Vlimmeren AE, Karandur D, Semmelman A, Shah NH. Deep mutational scanning of the multi-domain phosphatase SHP2 reveals mechanisms of regulation and pathogenicity. Nat Commun Nat Publishing Group. 2025;16:5464. https:\/\/doi.org\/10.1038\/s41467-025-60641-4.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"1679_CR55","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1038\/s41467-024-48481-0","volume":"15","author":"M Gr\u00f8nb\u00e6k-Thygesen","year":"2024","unstructured":"Gr\u00f8nb\u00e6k-Thygesen M, Voutsinos V, Johansson KE, Schulze TK, Cagiada M, Pedersen L, et al. Deep mutational scanning reveals a correlation between degradation and toxicity of thousands of aspartoacylase variants. Nat Commun. 2024;15:4026. https:\/\/doi.org\/10.1038\/s41467-024-48481-0.","journal-title":"Nat Commun"},{"key":"1679_CR56","doi-asserted-by":"publisher","unstructured":"Estevam GO, Linossi EM, Macdonald CB, Espinoza CA, Michaud JM, Coyote-Maestas W, et al. In: D\u00f6tsch V, editor. Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain. eLife. eLife Sciences Publications, Ltd; 2024; 12: RP91619. https:\/\/doi.org\/10.7554\/eLife.91619.","DOI":"10.7554\/eLife.91619"},{"key":"1679_CR57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13059-023-02880-6","volume":"24","author":"CB Macdonald","year":"2023","unstructured":"Macdonald CB, Nedrud D, Grimes PR, Trinidad D, Fraser JS, Coyote-Maestas W. DIMPLE: deep insertion, deletion, and missense mutation libraries for exploring protein variation in evolution, disease, and biology. Genome Biol. 2023;24:36. https:\/\/doi.org\/10.1186\/s13059-023-02880-6.","journal-title":"Genome Biol"},{"key":"1679_CR58","doi-asserted-by":"publisher","unstructured":"Estevam GO, Linossi E, Rao J, Macdonald CB, Ravikumar A, Chrispens KM, et al. In: Seeliger MA, Andreotti AH, editors. Mapping kinase domain resistance mechanisms for the MET receptor tyrosine kinase via deep mutational scanning. eLife. eLife Sciences Publications, Ltd; 2025; 13: RP101882. https:\/\/doi.org\/10.7554\/eLife.101882.","DOI":"10.7554\/eLife.101882"},{"key":"1679_CR59","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13059-017-1272-5","volume":"18","author":"AF Rubin","year":"2017","unstructured":"Rubin AF, Gelman H, Lucas N, Bajjalieh SM, Papenfuss AT, Speed TP, et al. A statistical framework for analyzing deep mutational scanning data. Genome Biol. 2017;18:150. https:\/\/doi.org\/10.1186\/s13059-017-1272-5.","journal-title":"Genome Biol"},{"key":"1679_CR60","doi-asserted-by":"publisher","unstructured":"Hidalgo F, Nocka LM, Shah NH, Gorday K, Latorraca NR, Bandaru P, et al. In: Andreotti A, Cole PA, Andreotti A, Salvi N, editors. A saturation-mutagenesis analysis of the interplay between stability and activation in Ras. eLife. eLife Sciences Publications, Ltd; 2022; 11: e76595. https:\/\/doi.org\/10.7554\/eLife.76595.","DOI":"10.7554\/eLife.76595"},{"key":"1679_CR61","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13059-020-02091-3","volume":"21","author":"AJ Faure","year":"2020","unstructured":"Faure AJ, Schmiedel JM, Baeza-Centurion P, Lehner B. DiMSum: an error model and pipeline for analyzing deep mutational scanning data and diagnosing common experimental pathologies. Genome Biol. 2020;21:207. https:\/\/doi.org\/10.1186\/s13059-020-02091-3.","journal-title":"Genome Biol"},{"key":"1679_CR62","doi-asserted-by":"publisher","unstructured":"Valenzuela LF, Francois P, Skotheim J. The Product neutrality function defining genetic interactions emerges from mechanistic models of cell growth. eLife [Internet]. eLife Sciences Publications Limited; 2025;14. https:\/\/doi.org\/10.7554\/eLife.105265.2.\u00a0 Cited 2026 Jan 17.","DOI":"10.7554\/eLife.105265.2"},{"key":"1679_CR63","doi-asserted-by":"publisher","unstructured":"Mani R, St.Onge RP, Hartman JL, Giaever G, Roth FP. Defining genetic interaction. Proc Natl Acad Sci. Proceedings of the National Academy of Sciences; 2008;105:3461\u20136. https:\/\/doi.org\/10.1073\/pnas.0712255105.","DOI":"10.1073\/pnas.0712255105"},{"key":"1679_CR64","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1126\/science.1180823","volume":"327","author":"M Costanzo","year":"2010","unstructured":"Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, et al. The Genetic Landscape of a Cell. Science. 2010;327:425\u201331. https:\/\/doi.org\/10.1126\/science.1180823.","journal-title":"Science"},{"key":"1679_CR65","doi-asserted-by":"publisher","first-page":"14734","DOI":"10.1073\/pnas.1906169116","volume":"116","author":"I Levin-Reisman","year":"2019","unstructured":"Levin-Reisman I, Brauner A, Ronin I, Balaban NQ. Epistasis between antibiotic tolerance, persistence, and resistance mutations. Proc Natl Acad Sci U S A. 2019;116:14734\u20139. https:\/\/doi.org\/10.1073\/pnas.1906169116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1679_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cels.2019.01.003","volume":"8","author":"CT Meyer","year":"2019","unstructured":"Meyer CT, Wooten DJ, Paudel BB, Bauer J, Hardeman KN, Westover D, et al. Quantifying drug combination synergy along potency and efficacy axes. Cell Syst. 2019;8:97\u2013e10816. https:\/\/doi.org\/10.1016\/j.cels.2019.01.003.","journal-title":"Cell Syst"},{"key":"1679_CR67","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.chembiol.2018.10.024","volume":"26","author":"L Koudelkov\u00e1","year":"2019","unstructured":"Koudelkov\u00e1 L, Pataki AC, Tolde O, Pavlik V, Nobis M, Gemperle J, et al. Novel FRET-Based Src Biosensor Reveals Mechanisms of Src Activation and Its Dynamics in Focal Adhesions. Cell Chem Biol Elsevier. 2019;26:255\u2013e2684. https:\/\/doi.org\/10.1016\/j.chembiol.2018.10.024.","journal-title":"Cell Chem Biol Elsevier"},{"key":"1679_CR68","doi-asserted-by":"publisher","unstructured":"Koudelkov\u00e1 L, Pelantov\u00e1 M, Br\u016fhov\u00e1 Z, Sztacho M, Pavl\u00edk V, P\u00e1nek D, et al. Phosphorylation of tyrosine 90 in SH3 domain is a new regulatory switch controlling Src kinase. In: Gould K, D\u00f6tsch V, Pons M, editors. eLife. eLife Sciences Publications, Ltd; 2023; 12: e82428. https:\/\/doi.org\/10.7554\/eLife.82428.","DOI":"10.7554\/eLife.82428"},{"key":"1679_CR69","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/s41587-023-02018-w","volume":"42","author":"E Ivorra-Molla","year":"2024","unstructured":"Ivorra-Molla E, Akhuli D, McAndrew MBL, Scott W, Kumar L, Palani S, et al. A monomeric StayGold fluorescent protein. Nat Biotechnol Nat Publishing Group. 2024;42:1368\u201371. https:\/\/doi.org\/10.1038\/s41587-023-02018-w.","journal-title":"Nat Biotechnol Nat Publishing Group"},{"key":"1679_CR70","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41592-023-01809-y","volume":"20","author":"TWJ Gadella","year":"2023","unstructured":"Gadella TWJ, van Weeren L, Stouthamer J, Hink MA, Wolters AHG, Giepmans BNG, et al. mScarlet3: a brilliant and fast-maturing red fluorescent protein. Nat Methods. 2023;20:541\u20135. https:\/\/doi.org\/10.1038\/s41592-023-01809-y.","journal-title":"Nat Methods"},{"key":"1679_CR71","unstructured":"Yurtsev E. eyurtsev\/fcsparser. 2025. https:\/\/github.com\/eyurtsev\/fcsparser.\u00a0Cited 2025 Jan 31. Accessed 31 Jan 2025."},{"key":"1679_CR72","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson J, Adler J, Dunger J, Evans R, Green T, Pritzel A, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nat Nat Publishing Group. 2024;630:493\u2013500. https:\/\/doi.org\/10.1038\/s41586-024-07487-w.","journal-title":"Nat Nat Publishing Group"},{"key":"1679_CR73","unstructured":"The PyMOL. Molecular Graphics System. Schr\u00f6dinger, LLC."},{"key":"1679_CR74","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.21105\/joss.03021","volume":"6","author":"ML Waskom","year":"2021","unstructured":"Waskom ML. seaborn: statistical data visualization. J Open Source Softw. 2021;6:3021. https:\/\/doi.org\/10.21105\/joss.03021.","journal-title":"J Open Source Softw"},{"key":"1679_CR75","doi-asserted-by":"publisher","unstructured":"Sokirniy I, Yang Z, Pritchard J. Figure 1 Base editor screen identifies asciminib resistance in ABL1 SH3, SH2, and kinase domains. 2026. https:\/\/doi.org\/10.6084\/M9.FIGSHARE.32130319.","DOI":"10.6084\/M9.FIGSHARE.32130319"},{"key":"1679_CR76","doi-asserted-by":"publisher","DOI":"10.1101\/2025.10.31.685392","author":"H Inam","year":"2025","unstructured":"Inam H, Tomaszkiewicz M, Reynolds J, Yang Z, Leighow S, Pritchard JR. Characterizing Variants of Uncertain Drug Resistance (VUDRs) Using Quantitative Measurements at Clinical Exposures. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.10.31.685392. 2025.10.31.685392.","journal-title":"bioRxiv"},{"key":"1679_CR77","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF, Part I. Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol Elsevier. 2007;8:1018\u201329. https:\/\/doi.org\/10.1016\/S1470-2045(07)70342-X.","journal-title":"Lancet Oncol Elsevier"},{"key":"1679_CR78","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/cts.13252","volume":"15","author":"M Hoch","year":"2022","unstructured":"Hoch M, Sengupta T, Hourcade-Potelleret F. Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants. Clin Transl Sci. 2022;15:1406\u201316. https:\/\/doi.org\/10.1111\/cts.13252.","journal-title":"Clin Transl Sci"},{"key":"1679_CR79","doi-asserted-by":"publisher","unstructured":"Sokirniy I, Yang Z, Pritchard J. Figure 2 Asciminib resistance hotspots in ABL1 kinase domain. 2026. https:\/\/doi.org\/10.6084\/M9.FIGSHARE.32130343.","DOI":"10.6084\/M9.FIGSHARE.32130343"},{"key":"1679_CR80","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"PW Manley","year":"2020","unstructured":"Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458. https:\/\/doi.org\/10.1016\/j.leukres.2020.106458.","journal-title":"Leuk Res"},{"key":"1679_CR81","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s40262-024-01428-6","volume":"63","author":"M Hoch","year":"2024","unstructured":"Hoch M, Huth F, Manley PW, Loisios-Konstantinidis I, Combes FP, Li YF, et al. Clinical Pharmacology of Asciminib: A Review. Clin Pharmacokinet. 2024;63:1513\u201328. https:\/\/doi.org\/10.1007\/s40262-024-01428-6.","journal-title":"Clin Pharmacokinet"},{"key":"1679_CR82","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-025-04755-y","volume":"95","author":"C Darstein","year":"2025","unstructured":"Darstein C, Yoon D, Yang Y, Kapoor S, Dasgupta K, Wu S, et al. Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol. 2025;95:39. https:\/\/doi.org\/10.1007\/s00280-025-04755-y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1679_CR83","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"MJ Mauro","year":"2023","unstructured":"Mauro MJ, Hughes TP, Kim D-W, Rea D, Cortes JE, Hochhaus A, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leuk Nat Publishing Group. 2023;37:1048\u201359. https:\/\/doi.org\/10.1038\/s41375-023-01860-w.","journal-title":"Leuk Nat Publishing Group"},{"key":"1679_CR84","doi-asserted-by":"publisher","unstructured":"Sokirniy I, Yang Z, Pritchard J. Figure 3 Asciminib resistance hotspots in ABL1 regulatory domains. 2026. https:\/\/doi.org\/10.6084\/M9.FIGSHARE.32130352.","DOI":"10.6084\/M9.FIGSHARE.32130352"},{"key":"1679_CR85","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adri\u00e1n FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting Bcr\u2013Abl by combining allosteric with ATP-binding-site inhibitors. Nat Nat Publishing Group. 2010;463:501\u20136. https:\/\/doi.org\/10.1038\/nature08675.","journal-title":"Nat Nat Publishing Group"},{"key":"1679_CR86","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0960-9822(95)00073-X","volume":"5","author":"BJ Mayer","year":"1995","unstructured":"Mayer BJ, Eck MJ. SH3 Domains: Minding your p\u2019s and q\u2019s. Curr Biol. 1995;5:364\u20137. https:\/\/doi.org\/10.1016\/S0960-9822(95)00073-X.","journal-title":"Curr Biol"},{"key":"1679_CR87","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","volume":"112","author":"O Hantschel","year":"2003","unstructured":"Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, et al. A Myristoyl\/Phosphotyrosine Switch Regulates c-Abl. Cell. 2003;112:845\u201357. https:\/\/doi.org\/10.1016\/S0092-8674(03)00191-0.","journal-title":"Cell"},{"key":"1679_CR88","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/ng0398-280","volume":"18","author":"D Baril\u00e1","year":"1998","unstructured":"Baril\u00e1 D, Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet Nat Publishing Group. 1998;18:280\u20132. https:\/\/doi.org\/10.1038\/ng0398-280.","journal-title":"Nat Genet Nat Publishing Group"},{"key":"1679_CR89","doi-asserted-by":"publisher","first-page":"7744","DOI":"10.1038\/sj.onc.1204978","volume":"20","author":"BB Brasher","year":"2001","unstructured":"Brasher BB, Roumiantsev S, Van Etten RA. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene Nat Publishing Group. 2001;20:7744\u201352. https:\/\/doi.org\/10.1038\/sj.onc.1204978.","journal-title":"Oncogene Nat Publishing Group"},{"key":"1679_CR90","doi-asserted-by":"publisher","first-page":"35631","DOI":"10.1074\/jbc.M005401200","volume":"275","author":"BB Brasher","year":"2000","unstructured":"Brasher BB, Etten RAV. c-Abl Has High Intrinsic Tyrosine Kinase Activity That Is Stimulated by Mutation of the Src Homology 3 Domain and by Autophosphorylation at Two Distinct Regulatory Tyrosines *. J Biol Chem Elsevier. 2000;275:35631\u20137. https:\/\/doi.org\/10.1074\/jbc.M005401200.","journal-title":"J Biol Chem Elsevier"},{"key":"1679_CR91","first-page":"1977","volume":"10","author":"RA Van Etten","year":"1995","unstructured":"Van Etten RA, Debnath J, Zhou H, Casasnovas JM. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene. 1995;10:1977\u201388.","journal-title":"Oncogene"},{"key":"1679_CR92","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/j.febslet.2012.04.054","volume":"586","author":"BA Liu","year":"2012","unstructured":"Liu BA, Engelmann BW, Nash PD. The language of SH2 domain interactions defines phosphotyrosine-mediated signal transduction. FEBS Lett. 2012;586:2597\u2013605. https:\/\/doi.org\/10.1016\/j.febslet.2012.04.054.","journal-title":"FEBS Lett"},{"key":"1679_CR93","first-page":"609","volume":"12","author":"BJ Mayer","year":"1992","unstructured":"Mayer BJ, Jackson PK, Van Etten RA, Baltimore D. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol Cell Biol. 1992;12:609\u201318.","journal-title":"Mol Cell Biol"},{"key":"1679_CR94","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1747-0285.2006.00361.x","volume":"67","author":"E Tokonzaba","year":"2006","unstructured":"Tokonzaba E, Capelluto DGS, Kutateladze TG, Overduin M, Phosphoinositide. Phosphopeptide and Pyridone Interactions of the Abl SH2 Domain. Chem Biol Drug Des. 2006;67:230\u20137. https:\/\/doi.org\/10.1111\/j.1747-0285.2006.00361.x.","journal-title":"Chem Biol Drug Des"},{"key":"1679_CR95","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1074\/jbc.R112.438382","volume":"288","author":"S Panjarian","year":"2013","unstructured":"Panjarian S, Iacob RE, Chen S, Engen JR, Smithgall TE. Structure and Dynamic Regulation of Abl Kinases*. J Biol Chem Elsevier. 2013;288:5443\u201350. https:\/\/doi.org\/10.1074\/jbc.R112.438382.","journal-title":"J Biol Chem Elsevier"},{"key":"1679_CR96","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/molbev\/msu301","volume":"32","author":"C Bank","year":"2015","unstructured":"Bank C, Hietpas RT, Jensen JD, Bolon DNA. A Systematic Survey of an Intragenic Epistatic Landscape. Mol Biol Evol. 2015;32:229\u201338. https:\/\/doi.org\/10.1093\/molbev\/msu301.","journal-title":"Mol Biol Evol"},{"key":"1679_CR97","doi-asserted-by":"publisher","unstructured":"Cortes JE, Hughes TP, Wang J, Kim D-W, Kim DDH, Mayer J, et al. Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial. Blood. 2025;blood2025029210. https:\/\/doi.org\/10.1182\/blood.2025029210.","DOI":"10.1182\/blood.2025029210"},{"key":"1679_CR98","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus A, Wang J, Kim D-W, Kim DDH, Mayer J, Goh Y-T, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med Mass Med Soc. 2024;391:885\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2400858.","journal-title":"N Engl J Med Mass Med Soc"},{"key":"1679_CR99","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1016\/j.clml.2018.06.031","volume":"18","author":"H Kim","year":"2018","unstructured":"Kim H, Kim S, Kim H-J, Kim Y-K, Kwak J-Y, Yhim H-Y, et al. Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic\u2013Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk Elsevier. 2018;18:e391\u20139. https:\/\/doi.org\/10.1016\/j.clml.2018.06.031.","journal-title":"Clin Lymphoma Myeloma Leuk Elsevier"},{"key":"1679_CR100","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","volume":"12","author":"S Soverini","year":"2006","unstructured":"Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12:7374\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1516.","journal-title":"Clin Cancer Res"},{"key":"1679_CR101","doi-asserted-by":"publisher","unstructured":"Sokirniy I, Yang Z, Pritchard J. Figure 4 Epistatic asciminib resistance by V73A and Y253H. 2026. https:\/\/doi.org\/10.6084\/M9.FIGSHARE.32130355.","DOI":"10.6084\/M9.FIGSHARE.32130355"},{"key":"1679_CR102","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/nsmb.3470","volume":"24","author":"T Saleh","year":"2017","unstructured":"Saleh T, Rossi P, Kalodimos CG. Atomic view of the energy landscape in the allosteric regulation of Abl kinase. Nat Struct Mol Biol Nat Publishing Group. 2017;24:893\u2013901. https:\/\/doi.org\/10.1038\/nsmb.3470.","journal-title":"Nat Struct Mol Biol Nat Publishing Group"},{"key":"1679_CR103","doi-asserted-by":"publisher","first-page":"eabc2754","DOI":"10.1126\/science.abc2754","volume":"370","author":"T Xie","year":"2020","unstructured":"Xie T, Saleh T, Rossi P, Kalodimos CG. Conformational states dynamically populated by a kinase determine its function. Science. 2020;370:eabc2754. https:\/\/doi.org\/10.1126\/science.abc2754.","journal-title":"Science"},{"key":"1679_CR104","doi-asserted-by":"publisher","unstructured":"Sokirniy I, Yang Z, Pritchard J, Figure. 5 ABL1 FRET biosensor corroborates functional resistance. 2026. https:\/\/doi.org\/10.6084\/M9.FIGSHARE.32130415.","DOI":"10.6084\/M9.FIGSHARE.32130415"},{"key":"1679_CR105","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","volume":"9","author":"JR LaRochelle","year":"2018","unstructured":"LaRochelle JR, Fodor M, Vemulapalli V, Mohseni M, Wang P, Stams T, et al. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition. Nat Commun Nat Publishing Group. 2018;9:4508. https:\/\/doi.org\/10.1038\/s41467-018-06823-9.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"1679_CR106","doi-asserted-by":"publisher","first-page":"10420","DOI":"10.1038\/ncomms10420","volume":"7","author":"S-C Tien","year":"2016","unstructured":"Tien S-C, Lee H-H, Yang Y-C, Lin M-H, Chen Y-J, Chang Z-F. The Shp2-induced epithelial disorganization defect is reversed by HDAC6 inhibition independent of Cdc42. Nat Commun Nat Publishing Group. 2016;7:10420. https:\/\/doi.org\/10.1038\/ncomms10420.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"1679_CR107","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ng1156","volume":"34","author":"M Tartaglia","year":"2003","unstructured":"Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet Nat Publishing Group. 2003;34:148\u201350. https:\/\/doi.org\/10.1038\/ng1156.","journal-title":"Nat Genet Nat Publishing Group"},{"key":"1679_CR108","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1021\/acs.jmedchem.0c01170","volume":"63","author":"MJ LaMarche","year":"2020","unstructured":"LaMarche MJ, Acker M, Argintaru A, Bauer D, Boisclair J, Chan H, et al. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem Am Chem Soc. 2020;63:13578\u201394. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01170.","journal-title":"J Med Chem Am Chem Soc"},{"key":"1679_CR109","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1038\/s41467-018-06814-w","volume":"9","author":"RAP P\u00e1dua","year":"2018","unstructured":"P\u00e1dua RAP, Sun Y, Marko I, Pitsawong W, Stiller JB, Otten R, et al. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2. Nat Commun Nat Publishing Group. 2018;9:4507. https:\/\/doi.org\/10.1038\/s41467-018-06814-w.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"1679_CR110","doi-asserted-by":"publisher","unstructured":"Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci. Proceedings of the National Academy of Sciences; 2013;110:E4437\u201345. https:\/\/doi.org\/10.1073\/pnas.1314712110.","DOI":"10.1073\/pnas.1314712110"},{"key":"1679_CR111","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1038\/s41467-019-12130-8","volume":"10","author":"FJ Poelwijk","year":"2019","unstructured":"Poelwijk FJ, Socolich M, Ranganathan R. Learning the pattern of epistasis linking genotype and phenotype in a protein. Nat Commun Nat Publishing Group. 2019;10:4213. https:\/\/doi.org\/10.1038\/s41467-019-12130-8.","journal-title":"Nat Commun Nat Publishing Group"},{"key":"1679_CR112","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nature17995","volume":"533","author":"KS Sarkisyan","year":"2016","unstructured":"Sarkisyan KS, Bolotin DA, Meer MV, Usmanova DR, Mishin AS, Sharonov GV, et al. Local fitness landscape of the green fluorescent protein. Nature. 2016;533:397\u2013401. https:\/\/doi.org\/10.1038\/nature17995.","journal-title":"Nature"},{"key":"1679_CR113","doi-asserted-by":"publisher","first-page":"6718","DOI":"10.3390\/ijms16046718","volume":"16","author":"D Shrestha","year":"2015","unstructured":"Shrestha D, Jenei A, Nagy P, Vereb G, Sz\u00f6ll\u0151si J. Understanding FRET as a Research Tool for Cellular Studies. Int J Mol Sci. 2015;16:6718\u201356. https:\/\/doi.org\/10.3390\/ijms16046718.","journal-title":"Int J Mol Sci"},{"key":"1679_CR114","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242\u20139. https:\/\/doi.org\/10.1182\/blood-2007-03-066936.","journal-title":"Blood"},{"key":"1679_CR115","doi-asserted-by":"publisher","first-page":"14","DOI":"10.6004\/jnccn.2025.5052","volume":"23","author":"G Shiller","year":"2025","unstructured":"Shiller G. Integrating New Therapies for the Treatment of Chronic-Phase Chronic Myeloid Leukemia. J Natl Compr Canc Netw. Natl Compr Cancer Netw. 2025;23:14\u20137. https:\/\/doi.org\/10.6004\/jnccn.2025.5052.","journal-title":"Natl Compr Cancer Netw"},{"key":"1679_CR116","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-024-01642-6","volume":"17","author":"TP Hughes","year":"2024","unstructured":"Hughes TP, Saglio G, Geissler J, Kim D-W, Lomaia E, Mayer J, et al. Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. J Hematol OncolJ Hematol Oncol. 2024;17:125. https:\/\/doi.org\/10.1186\/s13045-024-01642-6.","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"1679_CR117","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/s41375-025-02592-9","volume":"39","author":"JE Cortes","year":"2025","unstructured":"Cortes JE, Lang F, Rea D, Hochhaus A, Breccia M, Goh YT, et al. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leuk Nat Publishing Group. 2025;39:1124\u201334. https:\/\/doi.org\/10.1038\/s41375-025-02592-9.","journal-title":"Leuk Nat Publishing Group"},{"key":"1679_CR118","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adri\u00e1n FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting wild-type and T315I Bcr-Abl by combining allosteric with ATP-site inhibitors. Nature. 2010;463:501\u20136. https:\/\/doi.org\/10.1038\/nature08675.","journal-title":"Nature"},{"key":"1679_CR119","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1073\/pnas.0811912106","volume":"106","author":"RE Iacob","year":"2009","unstructured":"Iacob RE, Pene-Dumitrescu T, Zhang J, Gray NS, Smithgall TE, Engen JR. Conformational disturbance in Abl kinase upon mutation and deregulation. Proc Natl Acad Sci U S A. 2009;106:1386\u201391. https:\/\/doi.org\/10.1073\/pnas.0811912106.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1679_CR120","doi-asserted-by":"publisher","unstructured":"Starr TN, Flynn JM, Mishra P, Bolon DNA, Thornton JW. Pervasive contingency and entrenchment in a billion years of Hsp90 evolution. Proc Natl Acad Sci. Proceedings of the National Academy of Sciences; 2018;115:4453\u20138. https:\/\/doi.org\/10.1073\/pnas.1718133115.","DOI":"10.1073\/pnas.1718133115"},{"key":"1679_CR121","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1016\/j.celrep.2020.02.108","volume":"30","author":"SM Leighow","year":"2020","unstructured":"Leighow SM, Liu C, Inam H, Zhao B, Pritchard JR. Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design. Cell Rep. 2020;30:3951\u2013e39634. https:\/\/doi.org\/10.1016\/j.celrep.2020.02.108.","journal-title":"Cell Rep"},{"key":"1679_CR122","unstructured":"Sokirniy I, Yang Z, Pritchard J. TheBioinformatician\/Dual-Functional-Genomics-Asciminib. GitHub. 2026. https:\/\/github.com\/TheBioinformatician\/Dual-Functional-Genomics-Asciminib."},{"key":"1679_CR123","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.19902296","author":"I Sokirniy","year":"2026","unstructured":"Sokirniy I, Yang Z, Pritchard J. BCR::ABL1 Asciminib Resistance: Functional Genomics Analysis and Visualization Pipeline. Zenodo. 2026. https:\/\/doi.org\/10.5281\/zenodo.19902296.","journal-title":"Zenodo"},{"key":"1679_CR124","unstructured":"Sokirniy I, Yang Z, Pritchard J. Functional genomics reveals the mutational and epistatic basis of asciminib resistance. NCBI Sequence Read Archive. 2026. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA1307639."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01679-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01679-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:55:17Z","timestamp":1789390517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01679-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1679"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01679-x","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study used the commercially available human immortalized cell line K562 and the murine cell line Ba\/F3. Ethics committee approval and patient consent were not required, as no primary human or animal materials were utilized.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.R.P. is a co-founder of RedAce Bio. J.R.P. is a co-founder and consultant for Theseus Pharmaceuticals. J.R.P. received equity from Theseus Pharmaceuticals, MOMA therapeutics and RedAce Bio. J.R.P. has consulted\/consults for MOMA therapeutics, Curie.Bio, Third Rock Ventures, Takeda Pharmaceuticals, Galapagos Pharmaceuticals, and Roche\/Genentech. J.R.P. has received honoraria and travel expenses from Roche\/Genentech, Third Rock Ventures, and Theseus Pharmaceuticals. The remaining authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"114"}}